Search results for mRNA
Industry
Moderna shares surge 177 percent after success in phase 3 trial for mRNA cancer vaccine
Moderna shares jumped about 177 percent in a single day after the company reported positive results from the first phase 3 clinical trial of a personalised mRNA-based cancer treatment. Moderna said its intismeran autogene, used with Merck\'s Keytruda, met the main endpoints in the INTerpath-001 trial in patients with stage 2B to 4 melanoma after tumour removal surgery. Merck shares also rose. Short sellers\' losses widened to about $4.8 billion.
Industry
Hantavirus fears revive COVID-19 beneficiary stocks; Moderna and BioNTech in focus
Rising concerns about a possible spread of hantavirus are pushing medical and vaccine-related stocks back into focus after gaining attention during the COVID-19 pandemic. BeInCrypto reported that Moderna, Emergent BioSolutions and BioNTech entered reassessment phases in May. Moderna shares rose on stronger first-quarter sales, vaccine cooperation news and flu vaccine trial data publication. Emergent is focused on confirming a bottom amid weaker guidance. BioNTech faces a bearish technical pattern despite maintained revenue guidance.
Industry
KAIST develops mRNA platform that works well for ageing and obesity
KAIST said a joint research team developed a new mRNA platform by precisely designing the 5\' untranslated region, a key regulatory area that controls how efficiently proteins are produced. Using integrated analysis of large-scale bioinformatics data, the team identified 5\' UTR sequences that improve protein production across diverse cellular environments. In preclinical ageing and obesity models, an mRNA therapeutic based on the design increased protein production and immune responses compared with existing approaches.